

SKANDITEK

Industriförvaltning AB (publ)

Year-end report

January 1 – December 31, 2006

- Profit after taxes amounted to SEK 350.5 m (2005: 454.5)
- Capital gains on the divestment of shares in portfolio companies totaled SEK 187.6 m (376.4)
- Earnings per share, amounted to SEK 5.29 (7.52)
- Cash flow during the year amounted to SEK 118.9 m (23.4)
- The Board of Directors proposes a dividend of SEK 0.30 (0.20) per share and an extra dividend of SEK 0.20 (0)

Telephone conference today at 2:00 p.m.

A telephone conference in Swedish will be held today at 2:00 p.m. with Company President Patrik Tigerschiöld and Financial Manager Jonas Alfredson. The event is open to journalists and capital-markets professionals. If interested, call +46 8-672 81 50 well in advance of the conference.

Skanditek's operations

Skanditek is an industrial holding company with investments in Swedish companies. The Company's business concept is to generate sustainable and healthy value growth by means of industrial management of operational companies.

Investments are usually made at a stage when Skanditek can contribute business-development experience aimed at high and profitable growth.

Investment operations***Investments/divestments during the fourth quarter***

During the fourth quarter, investments of SEK 12.4 m (73.8) were made in portfolio companies, of which SEK 7.5 m was attributable to new subscription of shares in Bure Equity.

During the fourth quarter, Skanditek divested shares and securities in portfolio companies corresponding to SEK 2.7 m (24.4).

Total investments/divestments during January-December

Total investments in portfolio companies for the year amounted to SEK 14.0 m (759.1). In addition, Skanditek subscribed for a convertible subordinated loan of SEK 8 m issued by Theduction.

In June, Skanditek and the portfolio company H Lundén Holding each invested 13 percent in Menka Menkul Degerler (name being changed to Sardis Securities), a stockbroking company in Turkey. Skanditek's share of the investment amounts to SEK 1.2 m.

Divestments of shares and securities in portfolio companies during the year amounted to SEK 205.0 m (535.3). The primary divestments were as follows:

- Skanditek sold shares of Powerwave during the year for SEK 174.2 m.
- Skanditek sold shares of Axis during the year for SEK 29.3 m.

The Group's net investments in tangible fixed assets amounted to SEK 2.3 m (2.4).

A summary of Skanditek's holdings in portfolio companies following the transactions described above is presented on page 9.

Net sales and earnings

Consolidated net sales totaled SEK 784.1 m (700.1). The Group reported a pretax profit of SEK 344.7 m (458.3).

Capital gains on the divestment of portfolio companies totaled SEK 187.6 m (376.4). The capital gains derived from divestments in Powerwave of

SEK 171.8 m and in Axis of SEK 15.8 m. The divestments will not give rise to any tax consequences.

Profit of SEK 92.1 m (61.9) from associated companies consists primarily of shares in the profits of associated companies amounting to SEK 68.9 m (38.3) and a share in new-issue profits of associated companies amounting to SEK 23.3 m (19.8).

The change in fair value, pursuant to IAS 39, of currency futures and short-term investments had a positive effect of SEK 13.8 m (neg: 21.4) on the Group's income.

Consolidated net profit amounted to SEK 350.5 m (454.5), of which SEK 346.7 m (455.0) was attributable to shareholders in the Parent Company, corresponding to earnings per share of SEK 5.29 (7.52).

Since Skanditek has the character of an industrial holding company, analyses of the financial statements should be conducted with caution. Skanditek's composition in terms of Group and associated companies varies over time in line with changes in Skanditek's ownership shares in the portfolio companies.

Financial position

At the end of the year, the Group's cash and cash equivalents totaled SEK 173.1 m (56.0). In addition, there were short-term investments in mutual funds and publicly traded shares with a market value of SEK 45.2 m (8.0).

Cash and cash equivalents available for investment activities (excluding portfolio companies within the Group) amounted to SEK 98.2 m (6.6) and short-term investments to SEK 45.2 m (7.7). The Group had no interest-bearing liabilities (37.8).

Shareholders' equity corresponded to SEK 19.54 (15.55) per share. The increase was due mainly to profit and to an increase in the value of certain financial instruments reported at fair value in accordance with IAS 39. The change is reported against shareholders' equity. The equity/assets ratio in the Group was 89 percent (81).

Listed portfolio companies

At the end of the year, the market value of the Group's shareholdings in listed portfolio companies was SEK 1,209.5 m, corresponding to SEK 18.46 per share. On February 22, 2007, the corresponding values were SEK 1,172.0 m and SEK 17.89 per share, respectively. The carrying amount of the corresponding holdings at December 31 was SEK 719.7 m, or SEK 10.99 per share. The discrepancy between carrying amount and market value is due to Skanditek's listed associated companies being reported according to the equity method.

Sales and earnings in major portfolio companies

Amounts in SEK millions	Jan - Dec 2006			Jan - Dec 2005		
	Net sales	Operating profit/loss	Operating margin	Net sales	Operating profit/loss	Operating margin
Bure Equity	2,147.1	70.6	3.3	2,022.7	120.0	5.9
CMA Microdialysis	59.6	2.9	4.9	56.9	-9.1	-16.0
MYDATA automation	724.4	67.7	9.3	643.2	23.2	3.6
PartnerTech	3,057.2	180.0	5.9	2,013.9	88.1	4.4
Vitrolife	171.3	20.0	11.7	120.1	12.1	10.1

Performance of portfolio companies

Skanditek's share of the portfolio companies' net sales, calculated as the ownership share multiplied by the individual companies' net sales during the period when the companies were owned by Skanditek, amounted to SEK 2,233 m (1,538). Skanditek's holdings in Powerwave are excluded from the figures for 2006 because these are no longer regarded as holdings in a portfolio company but as a financial placement.

Similarly calculated, Skanditek's share of the portfolio companies' operating profit amounted to SEK 172 m (80).

Bure Equity

Overall, practically all of Bure's portfolio companies have performed well during the period. Bure's share of the portfolio companies' operating profit amounted to SEK 140 m (159).

Bure's operating profit amounted to SEK 139.6 m (459.7). The operating profit excluding exit profits and discontinued operations amounted to SEK 70.6 m (120.0).

IT Gymnasiet Sverige and Framtidsgymnasiet were acquired during the fourth quarter. The companies complement Bure's already existing holdings in the private-school market and bring annual billings for Bure's private schools, taken together, to SEK 700 m. The engineering consultancy Ergo was also acquired during the fourth quarter.

Systeam and Cygate were divested during the fourth quarter, resulting in a cash inflow of SEK 1.1 billion.

Bure's net cash holdings, which amounted to SEK 1.1 billion at year end, have subsequently increased by an additional SEK 1.1 billion due to the aforementioned divestments. Total net cash holdings presently amount to SEK 2.2 billion.

Over the past few years, Bure has solved its indebtedness problems and refined its operations concurrently with improvements in the profitability of its portfolio companies. Against this background, Bure's Board has decided to propose that the General Meeting approve an extraordinary distribution of capital to shareholders totaling approximately SEK 900 m during 2007. In addition,

expected subscription settlements from outstanding share warrants amounting to approximately SEK 500 m are expected to be returned to shareholders.

CMA Microdialysis

CMA continues to perform well in terms of profit and sales. Net sales amounted to SEK 59.6 m (56.9), corresponding to an increase of 5 percent. Operating profit amounted to SEK 2.9 m (loss: 9.1). The improvement in profitability was due to increased productivity, a transfer of production to low-cost countries and a favorable product mix.

CMA introduced a number of new products and entered a number of new distribution agreements during the quarter.

MYDATA Automation

Net sales for the year amounted to SEK 724.4 m (643.2). Order bookings during the year totaled SEK 725.5 m (645.3), a year-on-year increase of 12 percent. Operating profit amounted to SEK 67.7 m (23.2).

The proportion of investments in research and development amounted to 14 percent (15) of sales, for which SEK 98.7 m (96.8) was charged against earnings during the year. Cash flow from operating activities amounted to SEK 65.0 m (17.2).

Bengt Broman took over as President of Mydata on January 1, 2007. Bengt Broman previously served as President of LGP Algon when Skanditek had a major position in the company.

MY500

MY500 is Mydata's new product featuring an entirely new method for applying solder paste to circuit boards. In May 2006, Mydata reported that additional investments in development were necessary to meet the product's technical specifications. Further progress towards these specifications has been attained during the period and the previously reported projection that product objectives would be fulfilled during the first six months of 2007 remains unchanged.

PartnerTech

Net sales increased by 56 percent and totaled SEK 3,057.2 m (2,013.9). Growth for the period amounted to 52 percent and was attained through acquisitions and through organic growth in the form

of a number of larger orders from both new and previously existing customers. Sales growth for comparable entities was 23 percent.

Operating profit amounted to SEK 180.0 m (88.1). The improved operating profit compared with the preceding year was mainly due to sales growth. The operating margin was 5.9 percent (4.4).

PartnerTech continues to strengthen its positions in order to enhance its ability to offer a wide selection of services to an increased number of geographic markets.

Vitrolife

Net sales totaled SEK 171.3 m (120.1), up 43 percent. For comparable entities (including 2005 pro forma Swemed figures), the sales increase was 13 percent.

Operating profit amounted to SEK 20.0 m (12.1), including non-recurring expenses of SEK 2.1 m attributable to the acquisition of Swemed and to non-recurring revenues of SEK 3.6 m being included in the preceding year's profits. Excluding items of a non-recurrent character, operating profit increased by almost 170 percent compared with the previous year. Cash flow from operating activities amounted to SEK 23.8 m (14.1).

Positive synergies in the form of profits and cash flow attained in connection with the integration of Swemed are enhancing opportunities to make additional investments in Vitrolife's promising development projects and a number of product introductions during 2007

Parent Company

The Parent Company's net sales during 2006 amounted to SEK 0.1 m (0.1). A pretax profit of SEK 109.3 m (191.8) was reported. Profit consists primarily of a dividend of SEK 100.0 m received from the subsidiary G Kallstrom & Co AB. Otherwise, profit consists of administrative expenses, capital gains and dividends.

The Parent Company's investments in portfolio companies totaled SEK 15.0 m (676.1). Sales of portfolio companies corresponded to a value of SEK 30.8 m (603.0). Investments in tangible fixed assets during 2006 amounted to SEK 0.3 m (0.9).

Cash and cash equivalents at the end of the year totaled SEK 8.9 m (beginning of the year: 3.9). In addition, the Parent Company had short-term investments in mutual funds and publicly traded shares with a fair value of SEK 45.2 m (beginning of the year: 7.7). There were no interest-bearing liabilities (37.8). The equity/assets ratio was 89 percent (82).

Accounting principles

This year-end report is compiled in accordance with IAS 34 Interim Reporting, International Financial Reporting Standards – IFRS. The accounting principles described in this year-end report have been described in detail in Skanditek's 2005 annual report. The Group's accounting principles are unchanged from those applied during 2005.

As of January 1, 2006, IAS39 has been applied with regard to the Parent Company, entailing the valuation of certain financial instruments at fair value.

Proposed dividend

The Board of Directors proposes that the General Meeting approve a dividend of SEK 0.30 (0.20) per share for the 2006 fiscal year, as well as an extraordinary dividend of SEK 0.20 (0) per share.

Employees

The average number of employees in the Group during 2006 was 345 (348). The Parent Company had five employees (5), who comprise the investment-management organization.

Information

This year-end report has not been reviewed by the Company's auditors.

Following the end of the reporting period

Johan Björkman, Skanditek Board member since 1998 and Chairman from 1998 to 2004, passed away on February 12, 2007. Johan Björkman's considerable involvement in Skanditek and its portfolio companies has been important for long-term value growth. We will remember Johan, our colleague and friend, as a very intelligent and clearheaded person characterized by warmth, generosity and humor.

Annual General Meeting 2007

The 2007 Annual General Meeting will be held on March 26, 2007 at 5:00 p.m. in the Svenska Läkarsällskapet's conference facilities in Stockholm. See the notices in *Svenska Dagbladet* and *Post- och Inrikes Tidningar* and on the company's website. The Annual Report will be made available beginning March 5, 2007.

Nomination of Board members

The Nomination Committee consists of Tomas Fischer and Bob Persson. Proposals concerning Board members may be submitted in writing to the following address:

Skanditek Industriförvaltning AB
Valberedningen
Nybrogatan 6
SE-114 34 STOCKHOLM

Forthcoming financial reports

The scheduled publication dates for forthcoming financial reports are as follows:

Interim report, Jan-March 2007	May 4, 2007
Interim report Jan-June	July 17, 2007

Financial reports and press releases are published in

Swedish and English and are available on the Company's website at www.skanditek.se.

Stockholm, February 23, 2007

SKANDITEK INDUSTRIFÖRVALTNING AB (publ)
The Board of Directors

For further information, please contact:

Patrik Tigerschiöld, President,
Telephone +46-8-614 00 20

Jonas Alfredson, Financial Manager,
Telephone +46-8-614 00 29

Group income statements	12 months 2006 Jan-Dec	12 months 2005 Jan-Dec	3 months 2006 Oct-Dec	3 months 2005 Oct-Dec
Amounts in SEK thousands				
Net sales	784 099	700 146	224 826	222 439
Cost of goods sold	-468 734	-426 326	-140 664	-135 984
Gross profit	315 365	273 820	84 162	86 455
Result from participations in associated companies	92 146	61 855	11 235	16 763
Result from participations in other portfolio companies	188 065	378 163	0	24 701
Sales expenses	-113 193	-113 735	-35 153	-35 374
Administrative expenses	-53 295	-53 671	-13 440	-16 259
Research and development costs	-99 848	-62 631	-27 101	-18 095
Change in real value of financial instruments	13 829	-21 430	4 999	929
Other operating revenues and operating expenses	9 381	-4 875	4 152	-7 189
Operating profit/loss	352 450	457 496	28 854	51 931
<i>Result from financial investments</i>				
Interest income and similar profit/loss items	4 711	4 538	1 611	345
Interest expenses and similar profit/loss items	-12 509	-3 749	-4 113	-382
Profit after financial items	344 652	458 285	26 352	51 894
Taxes	5 799	-3 768	5 799	2 134
Net profit for the period	350 451	454 517	32 151	54 028
Attributable to:				
Parent Company shareholders	346 710	454 974	31 076	53 019
Minority shareholders	3 741	-457	1 075	1 009
Net profit for the period	350 451	454 517	32 151	54 028
Earnings per share after tax (excl. minority shareholders), SEK	5,29	7,52	0,47	0,81
Number of shares at the end of the period, thousands ¹⁾	65 505	65 505	65 505	65 505
Average number of shares, thousands	65 505	60 528	65 505	65 505

¹⁾There are no issued financial instruments that could give rise to more shares.

Group cash flow statements

	12 months 2006 Jan-Dec	12 months 2005 Jan-Dec	3 months 2006 Oct-Dec	3 months 2005 Oct-Dec
Amounts in SEK thousands				
Cash flow from operational activities before changes in working capital	62 689	55 097	17 048	58 719
Changes in working capital	-57 715	1 614	-17 658	-30 757
Cash flow from operational activities	4 974	56 711	-610	27 962
Cash flow from investment activities	171 523	-46 866	-16 060	-72 855
Cash flow from financial activities	-57 585	13 601	1 302	34 156
Cash flow for the period	118 912	23 446	-15 368	-10 737
Cash and cash equivalents, beginning of period	55 985	30 465	189 179	66 530
Exchange-rate differences in cash and cash equivalents	-1 786	2 074	-700	192
Cash and cash equivalents, period end	173 111	55 985	173 111	55 985

Group balance sheets

	2006 Dec 31	2005 Dec 31
Amounts in SEK thousands		
ASSETS		
Fixed assets		
Intangible assets	77 101	71 807
Tangible assets	5 123	5 997
Participations in associated companies	346 796	268 186
Participations in other portfolio companies	458 408	594 489
Other financial assets	28 670	21 972
Total fixed assets	916 098	962 451
Current assets		
Inventories, etc.	118 798	128 207
Current receivables	153 172	128 979
Accounts receivable	44 455	42 349
Short-term investments	50 451	8 023
Cash and bank balances	173 111	55 985
Total current assets	539 987	363 543
TOTAL ASSETS	1 456 085	1 325 994
EQUITY AND LIABILITIES		
Shareholders' equity (incl. minority interests)	1 300 080	1 032 891
Long-term liabilities		
Non-interest-bearing liabilities	1 148	678
Deferred tax liability	18 852	92 583
Total long-term liabilities	20 000	93 261
Current liabilities		
Interest-bearing liabilities	-	37 786
Accounts payable	48 259	68 477
Other non-interest-bearing liabilities	87 746	93 579
Total current liabilities	136 005	199 842
TOTAL EQUITY AND LIABILITIES	1 456 085	1 325 994

Change in Group equity

	Jan 1 - Dec 31, 2006			Jan 1 - Dec 31 2005		
	Attributable to Parent Company shareholders	Attributable to minority shareholders	Total	Attributable to Parent Company shareholders	Attributable to minority shareholders	Total
Amounts in SEK thousands						
Opening balance according to balance sheet	1 018 409	14 482	1 032 891	452 896	145 048	597 944
Effect of changed accounting principle, IAS 39 ¹⁾	-	-	-	290 792	95 480	386 272
Opening balance adjusted according to IAS 39	1 018 409	14 482	1 032 891	743 688	240 528	984 216
Change in financial instruments						
Change in financial assets available for sale	58 206	-	58 206	377 274	-7 417	369 857
Reversed to income statement during the year	-187 582	-	-187 582	-282 232	-90 331	-372 563
Changed tax effect	66 596	-	66 596	-55 009	13 299	-41 710
Change in equity, associated companies, IAS 39	3 409	-	3 409	4 767	-2 316	2 451
Translation differences	-8 398	75	-8 323	-6 702	7	-6 695
Non-Cash Issue	-	-	0	186 267	0	186 267
Acquisition of minority share in jointly owned subsidiary	-3 958	1 491	-2 467	-404 618	-138 831	-543 449
Dividend	-13 101	-	-13 101			0
Net profit/loss for the period	346 710	3 741	350 451	454 974	-457	454 517
Closing balance	1 280 291	19 789	1 300 080	1 018 409	14 482	1 032 891

¹⁾ Taking the tax effect into account.

Net sales per company

	12 months 2006 Jan-Dec	12 months 2005 Jan-Dec	3 months 2006 Oct-Dec	3 months 2005 Oct-Dec
Amounts in SEK thousands				
Skanditek Industriförvaltning	60	86	0	16
CMA Microdialysis AB	59 592	56 894	16 981	18 441
MYDATA automation AB	724 447	643 166	207 845	203 982
Group	784 099	700 146	224 826	222 439

Operating profit/loss per company

	12 months 2006 Jan-Dec	12 months 2005 Jan-Dec	3 months 2006 Oct-Dec	3 months 2005 Oct-Dec
Skanditek Industriförvaltning AB	103 523	211 404	-3 615	18 585
CMA Microdialysis AB	2 876	-9 064	1 685	-370
MYDATA automation AB	67 652	23 150	12 868	3 631
Other Group companies ¹⁾	172 781	303 444	-648	22 552
Share in earnings of associated companies	92 146	58 102	11 235	14 102
Change in financial instruments	13 829	-21 430	4 999	929
Group adjustments	-100 357	-108 110	2 330	-7 498
Group	352 450	457 496	28 854	51 931

¹⁾ Refers to companies that conduct portfolio management and securities trading activities and principally consists of dividends and capital gain

Key data, quarterly trend

	Q 1 2005	Q 2 2005	Q 3 2005	Q 4 2005	Q 1 2006	Q 2 2006	Q 3 2006	Q 4 2006
Market capitalization at period end, SEK m	1 381	1 503	2 018	2 345	3 177	2 515	2 705	2 791
Average market capitalization, SEK m ¹⁾	1 297	1 340	1 501	1 706	1 996	2 372	2 571	2 748
Market capitalization per share at period end, SEK	23,80	25,90	30,80	35,80	48,50	38,40	41,30	42,60
Market capitalization of listed holdings per share, SEK	15,75	15,54	15,97	18,30	17,75	15,99	17,90	18,46
Shareholders' equity per share, SEK	14,82	14,62	14,79	15,55	17,95	17,67	18,64	19,54
Invested capital, SEK m ²⁾	581	978	1 164	1 233	1 230	1 233	1 232	1 242
Invested capital per share, SEK	10,01	16,86	17,77	18,82	18,78	18,82	18,81	18,96
Management costs, SEK m (rolling 12-month basis)	13,1	13,3	15,7	17,1	18,6	20,1	18,8	17,7
Management costs/Market cap, % ³⁾	1,0	1,0	1,0	1,0	0,9	0,8	0,7	0,6
Equity/assets ratio, Group % ⁴⁾	86	83	81	78	86	88	89	89

¹⁾ Average market capitalization based on rolling 12-month periods.

²⁾ Invested capital from first investment occasion, incl. book value for share exchanges.

³⁾ Management costs based on rolling 12-month periods divided by average market capitalization.

⁴⁾ Equity/asset ratio includes minority interests

Skanditek's portfolio companies

Skanditek's portfolio companies and holdings shown as the percentage share of capital held on December 31, 2006 (excluding options).

COMPANY	NATURE OF BUSINESS	HOLDING
Electronics		
PartnerTech AB ¹⁾	Contract manufacturer within telecom, IT/mechatronics and medical equipment	37%
Mydata Automation AB	Advanced machinery for surface mounting of electronic components	95%
Services		
Aptilo Networks AB	System solutions for WLAN	10%
Bure Equity AB ¹⁾	Investment company that mainly invests in unlisted companies active in the service sector	10%
H Lundén Holding AB	Asset management	20%
PBK Outsourcing AB	Turnkey solutions for management accounting	46%
Theeducation AB	Develops new products and services for the education sector	48%
The Chimney Pot AB	Post-production and effects for film and video	36%
Biotechnology		
CMA Microdialysis AB	Medical devices	78%
Vitrolife AB ¹⁾	High-quality nutritional solutions for storage of organs, etc.	26%

¹⁾ Bure Equity, PartnerTech and Vitrolife are listed on the OMX Nordic Stock Exchange.

Skanditek Industriförvaltning AB (publ)

Nybrogatan 6 • 114 34 Stockholm • Sweden • Org No 556235-4141
 Phone +46-8-614 00 20 • Fax +46-8-614 00 38 • info@skanditek.se • www.skanditek.se